
Pulse Biosciences Reports Success in First-in-Human Study of Nano-PFA Cardiac Surgery System
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced that it successfully treated the first two patients in its initial human feasibility study using its innovative Cardiac Surgery System. This study, which employs the company’s proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology,…












